| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1048198006 |
| P356 | DOI | 10.2165/11318640-000000000-00000 |
| P698 | PubMed publication ID | 19708723 |
| P2093 | author name string | Maurizio Popoli | |
| P2860 | cites work | Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project | Q22242341 |
| Melatonin for the Treatment of Sleep Disturbances in Major Depressive Disorder | Q22306290 | ||
| The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways | Q28204452 | ||
| New approaches to antidepressant drug discovery: beyond monoamines | Q28293089 | ||
| Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. | Q33897785 | ||
| Severe depression: is there a best approach? | Q34401712 | ||
| Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial | Q34508971 | ||
| The interaction between the internal clock and antidepressant efficacy. | Q34583523 | ||
| Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial | Q34748493 | ||
| Daytime sleepiness and insomnia as correlates of depression. | Q35969989 | ||
| Biological rhythm disturbances in mood disorders | Q36377608 | ||
| Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system | Q36377612 | ||
| Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities | Q36637666 | ||
| Agomelatine: a preliminary review of a new antidepressant | Q36670845 | ||
| Organization and function of a central nervous system circadian oscillator: the suprachiasmatic hypothalamic nucleus | Q40090717 | ||
| Cost of depression in Europe | Q40284204 | ||
| Circadian rhythm mechanisms in affective illness and in antidepressant drug action | Q40326551 | ||
| New selective ligands of human cloned melatonin MT1 and MT2 receptors. | Q40645395 | ||
| Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. | Q40744982 | ||
| Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group | Q40840706 | ||
| Sleep research in depressive illness: clinical implications--a tasting menu | Q40938406 | ||
| Synaptic effects of antidepressants | Q41093393 | ||
| Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus | Q43569517 | ||
| DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee | Q44092710 | ||
| Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment | Q44102757 | ||
| Effect of agomelatine in the chronic mild stress model of depression in the rat. | Q44374779 | ||
| Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study | Q45004223 | ||
| Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. | Q46412677 | ||
| Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal | Q48521053 | ||
| The psychological aspects of patients with delayed sleep phase syndrome (DSPS) | Q48613364 | ||
| Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. | Q48708513 | ||
| Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). | Q48863278 | ||
| Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality | Q48941446 | ||
| Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. | Q52001622 | ||
| Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group | Q60705939 | ||
| Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent | Q71645337 | ||
| A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle | Q73081389 | ||
| Circadian rhythm of mt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse | Q73597638 | ||
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 27-34 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | Agomelatine: innovative pharmacological approach in depression | |
| P478 | volume | 23 Suppl 2 |
| Q36466559 | A comparative study of the clinical efficacy and safety of agomelatine with escitalopram in major depressive disorder patients: A randomized, parallel-group, phase IV study |
| Q37931969 | Agomelatine for the treatment of major depressive disorder |
| Q28651497 | Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks |
| Q24201746 | Agomelatine versus other antidepressive agents for major depression |
| Q24234339 | Agomelatine versus other antidepressive agents for major depression |
| Q24629465 | Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression |
| Q37678427 | Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy? |
| Q38427411 | Chronic stress impacts the cardiovascular system: animal models and clinical outcomes |
| Q37587157 | Disruption of the circadian timing systems: molecular mechanisms in mood disorders |
| Q28246147 | Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal |
| Q52654802 | Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical biology strategy. |
| Q38128733 | Leading compounds for the validation of animal models of psychopathology |
| Q96172053 | N-3 polyunsaturated fatty acids promote astrocyte differentiation and neurotrophin production independent of cAMP in patient-derived neural stem cells |
| Q37978196 | New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. |
| Q38203356 | Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder |
| Q26864049 | Profile of agomelatine and its potential in the treatment of generalized anxiety disorder |
| Q33549494 | Rodent models in depression research: classical strategies and new directions. |
| Q44036427 | Serotonin 2C receptor antagonists induce fast-onset antidepressant effects. |
| Q38366416 | The use of agomelatine in OCD: effects on the motivational aspects and dysregulated circadian rhythms |
| Q35353085 | Time-dependent activation of MAPK/Erk1/2 and Akt/GSK3 cascades: modulation by agomelatine. |
Search more.